Thyroid Cancer

Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules

Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules

By

Molecular testing may identify benign disease in some patients with thyroid nodules classified as suspicious for malignancy, helping them avoid unnecessary treatment.

Lobectomy Rates for Low-Risk DTC Are Rising

Lobectomy Rates for Low-Risk DTC Are Rising

By

Adherence to the 2015 recommendation from ATA — to use lobectomy rather than complete thyroidectomy for low-risk differentiated thyroid cancer — is increasing.

Malignancy Rates Higher in Children With Indeterminate Thyroid Nodules

Malignancy Rates Higher in Children With Indeterminate Thyroid Nodules

By

Malignancy was more common in children with thyroid nodules classified as indeterminate by BSRTC criteria compared with adults.

RET Inhibitor May Be Effective in <I>RET</I>-Altered Thyroid Cancers

RET Inhibitor May Be Effective in RET-Altered Thyroid Cancers

By

RET inhibitor LOXO-292 was well tolerated and demonstrated high antitumor activity against RET-altered thyroid cancers.

Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival

Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival

By

Childhood radiation-induced thyroid cancer does not affect all-cause mortality compared with healthy individuals.

MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer

MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer

By

The addition of selumetinib to radioactive iodine did not improve the complete remission rate among patients with high-risk nonmetastatic differentiated thyroid cancer.

Investigators Pinpoint Immune-Related Genes That Are Upregulated in ATC and PTC

Investigators Pinpoint Immune-Related Genes That Are Upregulated in ATC and PTC

By

Immune-related gene sets, including those for PD-L1/L2, are upregulated in ATC and PTC, but not in poorly differentiated disease or normal tissue.

US Centers Fail to Analyze Neck Lymph Nodes in Preoperative Ultrasounds for Thyroid Cancer

US Centers Fail to Analyze Neck Lymph Nodes in Preoperative Ultrasounds for Thyroid Cancer

By

Most imaging centers in the United States fail to analyze lateral neck lymph nodes during preoperative ultrasounds in patients with thyroid cancer.

PRRA Fails to Improve Long-Term Outcomes in Low-Risk Papillary Thyroid Cancer

PRRA Fails to Improve Long-Term Outcomes in Low-Risk Papillary Thyroid Cancer

By

Postoperative radioiodine remnant ablation did not improve long-term outcomes among patients with low-risk papillary thyroid carcinoma.

Recombinant Human Thyrotropin Use Has No Effect on Outcomes After Radioiodine in DTC

Recombinant Human Thyrotropin Use Has No Effect on Outcomes After Radioiodine in DTC

By

Outcomes after radioiodine therapy are similar after preparation with either recombinant human thyrotropin or thyroid hormone withdrawal.

Ethanol Sensitization May Improve RFA of Benign Thyroid Nodules

Ethanol Sensitization May Improve RFA of Benign Thyroid Nodules

By

Ethanol sensitization before radiofrequency ablation of benign thyroid nodules reduced time, ablation energy, and complications compared with conventional ablation.

Soluble PD-L1 Levels Associated With Disease-Free Survival in Papillary Thyroid Cancer

Soluble PD-L1 Levels Associated With Disease-Free Survival in Papillary Thyroid Cancer

By

High serum soluble PD-L1 levels are associated with shorter disease-free survival among patients with papillary thyroid cancer.

Thyroid irAEs Common With PD-L1 Inhibitors

Thyroid irAEs Common With PD-L1 Inhibitors

By

Thyroid-based immune-related adverse events are common among patients treated with PD-L1 inhibitors.

First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid Cancer

First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid Cancer

By

Pembrolizumab plus chemoradiotherapy failed to improve survival and lead to unexpected deaths in a small study of patients with anaplastic thyroid cancer.

TRK Inhibitor Effective in TRK-Fusion Advanced Thyroid Cancer

TRK Inhibitor Effective in TRK-Fusion Advanced Thyroid Cancer

By

The TRK inhibitor larotrectinib was effective and well tolerated among patients with relapsed/refractory advanced TRK-fusion thyroid cancer.

Several Driver Genes, Tumor Suppressors Found to Be Mutated in Anaplastic Thyroid Cancer

Several Driver Genes, Tumor Suppressors Found to Be Mutated in Anaplastic Thyroid Cancer

By

Tumor suppressor and driver genes are frequently mutated in Korean patients with anaplastic thyroid cancer.

Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid Cancer

Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid Cancer

For patients with low-risk thyroid cancer, ablation when indicated could be achieved with 1.1 GBq radioactive iodine after recombinant human thyroid-stimulating hormone (rhTSH) injections, as this combination reduces whole body irradiation and maintains quality of life.

Thymic Carcinoma: Pembrolizumab May Be An Effective Option

Thymic Carcinoma: Pembrolizumab May Be An Effective Option

By

Thymic carcinomas typically express high levels of PD-L1, leading researchers to predict a positive response to pembrolizumab.

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

By

The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.

Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment

Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment

By

Researchers enrolled 116 patients who were diagnosed with or were suspected of having thyroid cancer. The authors measured the growths' change in diameter to determine a growth pattern.

Dabrafenib Plus Trametinib May Be Effective Therapy for Thyroid Cancer

Dabrafenib Plus Trametinib May Be Effective Therapy for Thyroid Cancer

By

Patients with ATC have a very poor prognosis and are left with few systemic therapy options.

Cabozantinib Effective as Salvage Therapy in Thyroid Cancer

Cabozantinib Effective as Salvage Therapy in Thyroid Cancer

By

Significant clinical benefit was found in some patients treated with cabozantinib in the salvage setting.

USPSTF Recommends Against Thyroid Cancer Screening

USPSTF Recommends Against Thyroid Cancer Screening

By

The USPSTF stated that there was inadequate direct evidence for the benefits of screening.

Regorafenib Phase 2 Trial for Metastatic Medullary Thyroid Cancer

Regorafenib Phase 2 Trial for Metastatic Medullary Thyroid Cancer

By

Researchers are studying regorafenib, a multi kinase inhibitor, as treatment for metastatic medullary thyroid cancer.

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

By

Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.

RT Dose Associated With Improved Anaplastic Thyroid Cancer Survival

RT Dose Associated With Improved Anaplastic Thyroid Cancer Survival

By

Patients with unresected anaplastic thyroid carcinoma who receive greater than 60 Gy of radiation appear to have a longer median overall survival.

Crohn Disease and Thyroid Cancer: An Increased Risk?

Crohn Disease and Thyroid Cancer: An Increased Risk?

By

Crohn Disease (CD) may increase one's risk of thyroid cancer, according to an article published in Inflammatory Bowel Diseases.

USPSTF on Asymptomatic Thyroid Cancer: Do Not Screen Population

USPSTF on Asymptomatic Thyroid Cancer: Do Not Screen Population

By

The USPSTF recommends against population-wide screening for asymptomatic thyroid cancer.

Patient Age Linked With Survival in Papillary Thyroid Cancer

Patient Age Linked With Survival in Papillary Thyroid Cancer

For papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference.

Genomic Information and the Future of Health Care

Genomic Information and the Future of Health Care

By

Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs